3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
|
|
|
- CAS-Nr.
- 1092578-48-7
- Englisch Name:
- 3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
- Synonyma:
- 1-Piperidin;Tofacitinib-16;(3S,4R)-Tofacitinib;Tofatinib Impurity B;Tofacitinib Impurity 228;Tofacitinib Impurity FD+DX;YYMGYZDHOQYMFO-DGCLKSJQSA-N;Tofacitinib Impurity B(3S,4R);Tofacitinib Citrate Impurity 15;Azilsartan medoxomil impurity338
- CBNumber:
- CB32642728
- Summenformel:
- C16H20N6O
- Molgewicht:
- 312.3696
- MOL-Datei:
- 1092578-48-7.mol
|
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Eigenschaften
- Dichte
- 1.296
- storage temp.
- Store at -20°C
- L?slichkeit
- Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
- Aggregatzustand
- Powder
- pka
- 6.04±0.60(Predicted)
- InChI
- InChI=1/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13-/s3
- InChIKey
- UJLAWZDWDVHWOW-PZILLZCRNA-N
- SMILES
- C(#N)CC(N1CC[C@@H](C)[C@H](N(C)C2=NC=NC3NC=CC=32)C1)=O |&1:7,9,r|
Sicherheit
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
(3S,4R)-Tofacitinib is an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases.
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 104)Lieferanten
1092578-48-7()Verwandte Suche:
- 3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
- (3S,4R)-4-Methyl-3-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-beta-oxo-1-piperidinepropanenitrile
- (3S,4R)-Tofacitinib
- Tofacitinib Impurity B(3S,4R)
- YYMGYZDHOQYMFO-DGCLKSJQSA-N
- (3S,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile
- Tofacitinib Impurity FD+DX
- Tofacitinib Impurity B (3S,4R)-Tofacitinib
- Tofacitinib-16
- Tofacitinib impurity 12/(3S,4R)-Tofacitinib/3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitrile
- Azilsartan medoxomil impurity338
- 3-((3S,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanenitr
- Tofatinib Impurity B
- Tofacitinib Impurity 228
- 1-Piperidinepropanenitrile, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-, (3S,4R)-
- (3S,4R)-Tofacitinib (Tofacitinib Impurity)
- 1-Piperidin
- Tofacitinib Citrate Impurity 15
- 1092578-48-7
- 1885094-62-2
- 1174038-96-1
- 917389-32-4
- 119657-85-2
- 152-62-6
- 85847-53-7
- 2573767-91-5
- 65582-57-3
- 151878-23-9
- 16958-60-5
- 2189680-65-6
- 91059-01-8
- 145-15-4
- 1621681-63-8
- 58001-19-8
- 2564756-90-6
- 813425-83-2
- 1352804-27-4
- 1985606-48-2
- GYL
